Abstract:Innate immune pathways play a crucial role in the development of atherosclerosis, from sensing initial danger signals to the long-term reprogramming of immune cells. Despite the success of lipid-lowering therapy, anti-hypertensive medications, and other measures in reducing complications associated with atherosclerosis, cardiovascular disease (CVD) remains the leading cause of death worldwide. Consequently, there is an urgent need to devise novel preventive and therapeutic strategies to alleviate the global burden of CVD. Extensive experimental research and epidemiological studies have demonstrated the dominant role of innate immune mechanisms in the progression of atherosclerosis. Recently, landmark trials including CANTOS, COLCOT, and LoDoCo2 have provided solid evidence demonstrating that targeting innate immune pathways can effectively reduce the risk of CVD. These groundbreaking trials mark a significant paradigm shift in the field and open new avenues for atheroprotective treatments. It is therefore crucial to comprehend the intricate interplay between innate immune pathways and atherosclerosis for the development of targeted therapeutic interventions. Additionally, unraveling the mechanisms underlying long-term reprogramming may offer novel strategies to reverse the pro-inflammatory phenotype of immune cells and restore immune homeostasis in atherosclerosis. In this review, we present an overview of the innate immune pathways implicated in atherosclerosis, with a specific focus on the signaling pathways driving chronic inflammation in atherosclerosis and the long-term reprogramming of immune cells within atherosclerotic plaque. Elucidating the molecular mechanisms governing these processes presents exciting opportunities for the development of a new class of immunotherapeutic approaches aimed at reducing inflammation and promoting plaque stability. By addressing these aspects, we can potentially revolutionize the management of atherosclerosis and its associated cardiovascular complications.

Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications

Wnt signaling in cardiovascular physiology

Wnt signaling in cardiac development and heart diseases

Wnt Signaling in Atherosclerosis: Mechanisms to Therapeutic Implications

Nanocarrier Based Targeting of Vascular Cell Adhesion Molecule-1 for Diagnosis and Treatment of Atherosclerosis: Current Status and Future Perspectives

Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities

Significance of the Wnt signaling pathway in coronary artery atherosclerosis

WNT/β‐catenin pathway is a key regulator of cardiac function and energetic metabolism

The β-catenin C terminus links Wnt and sphingosine-1-phosphate signaling pathways to promote vascular remodeling and atherosclerosis

The role of -catenin in cardiac diseases

Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives

Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities

Non‐coding RNAs to treat vascular smooth muscle cell dysfunction

Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming

Wnt signaling pathways in myocardial infarction and the therapeutic effects of Wnt pathway inhibitors

Roles of Non-Canonical Wnt Signalling Pathways in Bone Biology

Targeting Canonical Wnt-signaling Through GSK-3β in Arrhythmogenic Cardiomyopathy: Conservative or Progressive?

Wnt Signaling in Heart Development and Regeneration